These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7630228)

  • 1. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
    Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevalence of anti-HAV antibodies and efficacy of pre-vaccine detection at institutions for mentally retarded of the city of Alicante].
    Martínez-Campillo F; Terán M; Alvarez M; Rigo MV; Roda J; Salinas M; García JM
    Aten Primaria; 2000 May; 25(8):552-5. PubMed ID: 10876948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries.
    Bayas JM; González A; Vilella A; San-Martín M; Bertran MJ; Adell C
    Epidemiol Infect; 2001 Oct; 127(2):347-51. PubMed ID: 11693513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prevalence of markers for the hepatitis A and B viruses in the population of Gijón between 6 and 25 years old].
    Suárez A; Navascués CA; García R; Peredo B; Miguel D; Menéndez MT; Saro C; Román F
    Med Clin (Barc); 1996 Apr; 106(13):491-4. PubMed ID: 8992130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening travelers for hepatitis A antibodies: an observational cost-comparison study of vaccine use.
    Lee KK; Beyer-Blodget J
    West J Med; 2000 Nov; 173(5):325-9. PubMed ID: 11069868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Need for vaccination of susceptible food handlers against hepatitis A in Taiwan.
    Yu MI; Lee SD; Lu RH; Chan CY; Wang YJ; Chang FY; Lo KJ
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Nov; 63(11):798-803. PubMed ID: 11155755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination strategies against hepatitis A in travelers older than 40 years: an economic evaluation.
    Costas L; Vilella A; Trilla A; Serrano B; Vera I; Roldán M; Sancho MP; Bayas JM; Gascón J; Costa J
    J Travel Med; 2009; 16(5):344-8. PubMed ID: 19796106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization.
    Domínguez A; Bruguera M; Plans P; Costa J; Salleras L
    J Med Virol; 2004 Jun; 73(2):172-6. PubMed ID: 15122789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic hepatitis C and risk for hepatitis A infection].
    Chlabicz S; Grzeszczuk A
    Przegl Epidemiol; 2001; 55(3):281-6. PubMed ID: 11761835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency of prevaccination screening of anti-HBc in the anti-hepatitis B vaccination programs].
    Navas E; Bayas JM; Taberner JL; Salleras L
    Med Clin (Barc); 1992 Nov; 99(17):641-4. PubMed ID: 1447934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the efficiency of the screening of anti-HVA IgG antibodies before active or passive immunization].
    Arnal Alonso JM; Frisas Clavero O; Garuz Bellido R; Forcen Alonso T
    Rev Sanid Hig Publica (Madr); 1995; 69(1):71-8. PubMed ID: 7644884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of hepatitis A and hepatitis E infection and their determinants in adult Chinese community in Hong Kong.
    Wong KH; Liu YM; Ng PS; Young BW; Lee SS
    J Med Virol; 2004 Apr; 72(4):538-44. PubMed ID: 14981755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccination against viral hepatitis A and B in adults aged over 40 years--antibody persistence and immune memory].
    Chlibek R; Smetana J; Bostíková V; Splino M
    Epidemiol Mikrobiol Imunol; 2011 Sep; 60(3):99-108. PubMed ID: 22132651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989-1996. Implications for new vaccination strategy].
    Bruguera M; Salleras L; Plans P; Vidal J; Navas E; Domínguez A; Batalla J; Taberner JL; Espuñes J
    Med Clin (Barc); 1999 Mar; 112(11):406-8. PubMed ID: 10231772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination.
    Saab S; Martin P; Yee HF
    Am J Med; 2000 Aug; 109(3):241-4. PubMed ID: 10974188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.